Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen receptor (ER) regulatory pathways and play roles in energy and lipid metabolism. Here, we analysed the functional role of ERRb in prostate cancer cell growth regulation in an androgen-sensitive and androgen-insensitive prostate cancer cell lines. ERRb was expressed in normal human prostates, but exhibited a reduced expression in prostate cancer lesions. Stable ERRb expression suppressed significantly cell proliferation and tumorigenicity of LNCaP and DU145 cells, accompanied by an S-phase suppression and increased p21 expression. Reporter and chromatin immunoprecipitation assays showed that ERRb could directly transactivate p21 gene promoter, which could be further enhanced by peroxisome proliferatoractivated receptor-c coactivator-1a. Truncation analysis showed that ERRb-mediated p21 transactivation and prostate cancer cell growth inhibition required intact DNA-binding domain and AF2 domains in ERRb. Interestingly, ERRb displayed a cell cycle associated downregulated expression pattern in ERRb-transduced and non-transduced cells. Finally, we showed that ERRbmediated growth inhibition could be potentiated by an ERRb/c agonist DY131. Knockdown of ERRb by RNA interference could reduce the DY131-induced growth inhibition in prostate cancer cells. Taken together, our findings indicate that ERRb performs a tumor suppressing function in prostate cancer cells, and targeting ERRb could be a potential therapeutic strategy for prostate cancer.
Introduction
Estrogen has been proposed for a long time to perform roles, such as epithelial-stromal interactions, in the normal development of prostate gland. On the contrary, abnormal elevation of estrogen or its exogenous exposure in men has been correlated to the development of prostate cancer, benign prostatic hyperplasia and abacterial prostatitis (Griffiths, 2000; Ho, 2004; Ho et al., 2004) . Conventionally, it is believed that direct estrogenic effects in developing or neoplastic prostates are mostly mediated through estrogen receptors (ERs), ERa and ERb, via regulation of their target gene expression or activation of estrogen signalings in prostatic cells (Weihua et al., 2002; Prins et al., 2006) .
Recent studies indicate that members of nuclear receptor (NR) subfamily NR3B, estrogen-related receptors (estrogen receptor-related receptors, ERRs), are structurally and functionally related to ERs and are involved in diverse metabolic, developmental and cell differentiation processes. ERRs consist of three closely related members (ERRa/b/g), each encoded by three different genes. All ERRs share high homology with ERs in their protein structures, particularly in their DNA-binding domain (DBD) and ligand-binding domains (LBD), DNA response elements and target genes, co-regulatory proteins, and binding to synthetic ligands in many target cells and tissues (Gigue`re, 2002) . However, ERRs are orphan nuclear receptors and constitutively active without binding to physiological estrogen. Therefore, it is viewed that the ligand-independent ERRs may functionally crosstalk with ERs in estrogen signaling or modulate estrogen responsiveness in target cells, which co-express both receptor types via competition for DNA-binding sites and coactivators, or ERRs may function independently via novel signaling pathways.
Human ERRb (ESRRB/ERR2/ERRb/ESRL2/ NR3B2) together with ERRa are the first two orphan NRs identified via screening tissue cDNA libraries with a human ERa-DBD probe (Gigue`re et al., 1988) and cloned again subsequently by PCR from various human organ cDNA (Chen et al., 1999) . Mouse and rat ERRbs were then cloned by RACE (rapid amplification of cDNA ends)-PCR in embryonal carcinoma stem cells (Pettersson et al., 1996) and rat prostate (Lui et al., 2006) . Three splice isoforms of human ERRb, derived from alternative splicing at the 3 0 -end, have been cloned from human fetal heart and testis cDNA, including hERRb2, hERRb2-D10 and short-form hERRb, with the short-form hERRb displaying a widespread tissue expression pattern (Chen et al., 1999; Zhou et al., 2006) . However, functional differences among these splice variants and their protein expressions in cells and tissues are unclear. Early expression studies show that ERRb exhibits a specific and restricted expression pattern confined to extraembryonic and few adult tissues, as compared to the relatively broader expression spectra of ERRa and ERRg. By northern blot, ERRb mRNA is expressed at weak levels in rat heart, kidney, brain and prostate (Gigue`re et al., 1988) , whereas in situ hybridization shows that ERRb transcripts are detected only during a narrow developmental window in mouse trophoblast progenitor cells, primordial and gonadal germ cells, and human placental tissue (Pettersson et al., 1996; Luo et al., 1997; Tanaka et al., 1998; Mitsunaga et al., 2004; Fujimoto et al., 2005) . However, recent studies by reverse transcription-PCR (RT-PCR) show that ERRb transcripts are widely expressed in many human and mouse tissues and organs Zhou et al., 2006) , suggesting that ERRb may participate in more diverse transcriptional and metabolic regulations than initially thought. Targeted disruption of ERRb in ERRb-knockout mice induces abnormal placenta development with the mutants dying prenatally, suggesting that ERRb plays a role in placental formation (Luo et al., 1997) . Similar to ERa and other ERR subtypes, ERRb can bind to the classical palindromic estrogen response element (ERE; AGGTCAnnnTGA CCT) in vitro and some direct repeat elements with extended half-site sequence (ERRE/SFRE; TNAAGG TCA or TCAA/GGGTCA), including thyroid hormone response element (Pettersson et al., 1996; Vanacker et al., 1999; Xie et al., 1999) . Moreover, similar to ERa, all ERRs including ERRb can transactivate Sp1 target genes via indirect interaction with the Sp1 transcription factor (Castet et al., 2006) . Thus, ERRb may crosstalk with ERa or other ERR subtypes at transcriptional level in target cells. Similar to ERRa, constitutive transactivation of ERRb depends on its binding via the LBD/AF2 domain with some NR coactivators, including GRIP1 (glucocorticoid receptor interacting protein 1), SRC-1 (steroid receptor coactivator-1), ACTR (activator of thyroid and retinoic acid receptor) (Xie et al., 1999) and peroxisome proliferator-activated receptor-g coactivator-1b (PGC-1b) (Kamei et al., 2003) , but suppressed by the receptor-interacting protein 140 (Castet et al., 2006) . Compared to ERRa and ERRg, functional studies on ERRb are relatively neglected. Information on ERRb target genes is scarce so far, although its metabolic roles still remain unknown. It has been shown that ERRb can activate the estrogen-inducible pS2, p21 and thyroid hormone receptor-a gene promoters in breast cancer cell lines (Lu et al., 2001; Castet et al., 2006) , and repress the glucocorticoid receptor transcriptional activity in a cell type-specific manner (Trapp and Holsboer, 1996) .
We demonstrated previously that members of ERRs and ERs are co-expressed in normal prostatic epithelial cells and exhibit differential expression patterns in neoplastic prostatic tissues (Cheung et al., 2005) , suggesting that the ligand-independent ERRs and ligand-dependent ERs may co-regulate the growth and functions of prostatic cells. Among ERRs, ERRb and ERRg, which are closely related in their structures, display an apparent downregulation pattern in prostate cancer cells and lesions. Recently, we have demonstrated that ERRg may perform an antiproliferative or tumorsuppressing function in prostate cancer cells, as its ectopic expression can induce a cell-cycle arrest at G 1 -S transition (Yu et al., 2007) . To elucidate the functional significance of ERRb in the growth regulation of prostate cancer cells and also its potential use as a novel biomarker or therapeutic target for this disease, in this study we investigated the effects of stable expression of ERRb in both androgen-sensitive (LNCaP) and androgen-insensitive (DU145) prostate cancer cells by retroviral transduction. Moreover, the involvement of cell-cycle regulatory protein p21 WAF1/CIP1 (p21) in ERRb-induced cell-cycle arrest and its transcriptional regulation by ERRb was also investigated. Finally, we examined the effects of a characterized transcriptional coactivator PGC-1a (Puigserver and Spiegelman, 2003) on the ERRb-mediated p21 gene promoter activation and in vitro growth effect of a selective ERRb/g agonist on prostate cancer cells.
Results

ERRb is downregulated in prostate cancer cells and carcinoma lesions
We previously reported that ERRb exhibits a downregulation pattern in many prostate cancer cell lines and prostatic neoplastic lesions (Cheung et al., 2005) . In this study, we analysed the expression profile of three splice variants of ERRb, as identified by Zhou et al. (2006) , in a panel of immortalized non-transformed prostatic epithelial cell and cancer lines. We determined that only the short-form ERRb transcripts (hereafter referred to as ERRb) but not ERRb2 and ERRb2-D10 were detected in all examined cell lines, with relatively higher expression levels in immortalized cell lines (RWPE-1, RWPE-2, PZ-HPV-7, HPr-1, HPr-1AR, PWR-1E, PNT1A, PNT2, BPH-1) than cancer lines (CA-HPV-10, LNCaP, C4-2B, DU145, PC-3, MDAPCa2b, CWR22Rv1) ( Figure 1a) . Immunohistochemistry of ERRb revealed that in fetal prostate, the epithelial cells of developing acini in proximal periurethral region expressed moderate ERRb immunosignals in their nuclei, whereas the budding acini in outer region exhibited more intense immunoreactions, with the positively stained cells arranged in groups in epithelial outgrowths. Stromal mesenchymal cells also showed positive nuclear staining. In pubertal prostate, the acinar epithelial and stromal cells expressed intense nuclear staining. The aged normal prostate also showed similar immunostaining in acinar cell nuclei but with reduced intensity. In prostatic intraepithelial neoplasia (PIN) lesions, the premalignant dysplastic epithelial cells displayed a distinct reduced expression pattern, with most of the luminal dysplastic cells expressing weak or negative nuclear staining, whereas the basal epithelial cells remained moderately stained in their nuclei. In well-differentiated adenocarcinoma lesions, the neoplastic cells expressed variable but reduced nuclear immunosignals (Figure 1b) .
Downregulation of ERRb in prostate cancer cells involves histone deacetylation
We next investigated whether epigenetic modifications could contribute to the downregulation of ERRb in prostate cancer cells. We found that treatments with two histone deacetylase inhibitors, trichostatin A (TSA) and sodium butyrate (NaBut), increased the ERRb mRNA expression in LNCaP, DU145 and PC-3 cells, with NaBut showing consistent higher capacity on increasing ERRb expression in all tested cancer cell lines (Figure 2 ). The DNA methylation inhibitor 5-aza-2 0 -deoxycytidine (5-Aza-dC) also induced a slight increased ERRb expression in LNCaP and PC-3 cells but not in DU145 cells. Our results suggest that histone deacetylation or endogenous histone deacetylase activities, and with lesser extent by DNA methylation, contribute to the downregulation of ERRb in prostate cancer cells.
ERRb overexpression induces morphological changes in LNCaP prostate cancer cells
To further manifest the functional significance of ERRb in prostate cancer cell growth, we generated ERRb-stable clones in LNCaP and DU145 prostate cancer cell lines by retroviral infection for in vitro and in vivo growth studies (Figures 3a and b) . DU145-ERRb clones displayed no significant morphological changes. However, we observed noticeable morphological changes in LNCaP-ERRb cells, which appeared multipolar with prominent long dendritic cell processes as compared to pBabe clones and parental cells (Figure 3c ). Immunoblot analysis revealed an increased neuron-specific enolase (NSE) expression and a decreased androgen receptor (AR) expression in LNCaP-ERRb clones (Figure 3b ). However, no chromogranin A or glial fibrillary acidic protein was detected in LNCaP-ERRb cells (data not shown). We also noted that ERRb suppresses prostate cancer cell growth S Yu et al the extent of increased NSE and decreased AR expression seemed to correlate positively with the relative ERRb expression levels in LNCaP-ERRb clones. We next investigated in detail the morphological changes in LNCaP-ERRb cells by cellular staining of mitochondria and lipid and transmission electron microscopy. We examined the mitochondrial integrity in live LNCaPERRb cells using a mitochondrial-selective membrane potential-dependent fluorescent probe JC-1. Confocal microscopy revealed that there was a significant increase of large red fluorescent mitochondria in LNCaP-ERRb cells than in parental cells (which contained mostly green fluorescent mitochondria) (Figure 4a ), indicating that the LNCaP-ERRb cells contained more active mitochondria at high membrane potentials. Oil-red-O staining showed that there was a significant increased accumulation of lipid droplets in LNCaP-ERRb cells, as compared to parental cells (Figure 4b ). Ultrastructural examination confirmed that there was a prominent increase of giant mitochondria with tubular cisternae and occasionally myelin-like lipid deposits, and lipid vesicles containing thin to moderate electron-dense contents in LNCaPERRb cells (Figure 4c) . A moderate increase in number of normal-sized mitochondria at high membrane potential and lipid droplets was also seen in DU145-ERRb cells (data not shown). Taken together, these results suggest that a neuroendocrine (NE)-like transdifferentiation was induced in LNCaP-ERRb cells, whereas both ERRb clones showed altered mitochondrial physiology and lipid metabolism.
Ectopic ERRb expression inhibits in vitro growth of prostate cancer cells All generated LNCaP-ERRb and DU145-ERRb clones proliferated significantly slower than their respective pBabe clones and parental cells (Figure 5a ). Soft agar assay for anchorage-independent growth demonstrated that LNCaP-ERRb clones formed less and smaller clones, whereas DU145-ERRb clones did not form any colonies in agar, independent of cell-seeding densities, as compared to their pBabe clones and parental cells that formed sizeable colonies in agar within 3-4 weeks ( Figure 6a ).
Ectopic ERRb expression suppresses in vivo tumor growth of prostate cancer cells
We next examined the effect of ectopic ERRb expression on the tumorigenicity of LNCaP and DU145 cells in immunodeficient mice. We showed that mice inoculated with LNCaP-ERRb clones did not develop tumors, whereas mice with DU145-ERRb clones formed smaller tumors, as compared with mice bearing with their pBabe clones and parental cells that developed tumors within 2 months (Figure 6b ).
Inhibition of prostate cancer cell growth by ERRb is mediated through an S-phase blockade As ectopic ERRb expression suppressed both in vitro and in vivo growth of prostate cancer cells, we next investigated the status of cell-cycle progression, apoptosis ERRb exhibits a cell-cycle-associated downregulated pattern in prostate cancer cells By immunofluorescence, we observed an ERRb expression pattern that ERRb infectants at interphase expressed intense nuclear staining, whereas the mitotic cells did not express ERRb ( Figure 7a ). We then sought to find out whether the ERRb expression in ERRb 
Cell-cycle arrest in prostate cancer cells by ERRb is accompanied with upregulation of p21
We next studied whether the arrest of cell-cycle progression at G 1 /S transition in ERRb-transduced prostate cancer cells could be associated with altered expression of cell-cycle regulatory proteins. Immunoblot analysis showed that there was a moderate increased expression of cyclin-dependent kinase inhibitor p21, but no significant changes of p27 and cyclins in both LNCaP-ERRb and DU145-ERRb clones (Figure 8a ). Interestingly, we also noted a positive correlation between the induced increased p21 expression levels and the ectopic ERRb levels in the ERRb-transduced clones (comparing clones LNCaP-ERRb nos. 1, 2 and 4, DU145-ERRb nos. 1 and 3 in Figures 3b and 8a ).
ERRb-mediated direct transactivation of p21 gene can be potently enhanced by PGC-1a We next determined whether the increased p21 protein expression in ERRb-transduced prostate cancer cells could be mediated through a direct transactivation of its gene promoter by ectopic ERRb or indirect responses to inhibitory cell growth-related signals induced by ERRb overexpression. Results of reporter assay showed that ectopic ERRb could moderately transactivate the 2-kb p21 promoter in PC-3 prostate cancer cell line and two non-prostate cancer lines (HeLa and HEK293 (human embryonic kidney cells)), indicating that ERRb could activate the p21 gene promoter and ERRb-mediated transactivation of p21 gene was not cell-type specific. We next performed the ChIP (chromatin immunoprecipitation) assay to determine whether ERRb could interact directly with the p21 promoter. Results showed that a 141-bp p21 promoter fragment was strongly amplified by PCR in immunoprecipitated DNA extracted in 293 cells transiently expressing ERRb and weakly in cells transfected with ERRbDZFI, but barely detected in cells transfected with empty vector pcDNA3.1 (parental 293 cells expressed endogenous ERRb). Taken together, these results demonstrated that ERRb could bind to the p21 promoter in vivo and the binding was mediated mainly through its DBD (Figure 8c ). We also demonstrated that the ERRbactivated p21 gene transactivation could be further stimulated by co-transfection with PGC-1a in a dosedependent manner (Figure 8d ). However, transfection with PGC-1a alone could only minimally activate the p21-Luc reporter.
ERRb-mediated p21 transactivation and growth inhibition requires intact DBD and AF2 To show whether the ERRb-induced p21 gene transactivation and growth inhibition in prostate cancer cells would require intact DBD and LBD/AF2, we generated ERRb-truncated mutants with deletion of the first zinc finger in its DBD (ERRbDZF1) or deletions of LBD and AF2 (ERRbDLBD-AF2 and ERRbDAF2) (Figure 9a ). Results of reporter assays showed that the mutant ERRbDZF1 was unable to transactivate the ERE/ ERRE/p21-Luc reporters (Figure 9b ). ERRb-mediated p21 transactivation, which could be potentiated by PGC-1a, was not activated when transfected with the mutants ERRbDLBD-AF2 and ERRbDAF2 (Figure 9c ). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that all truncated mutants proliferated at faster rates than ERRb infectants (Figure 9d ). Taken together, these results suggested that ERRb-mediated p21 transactivation and growth inhibition required intact DBD and AF2 domains in ERRb.
ERR agonist potentiates ERRb-induced growth inhibition of prostate cancer cells As ERRb induced an antiproliferative effect in prostate cancer cells, we finally examined whether ERRb could be a potential therapeutic target in prostate cancer by testing the efficacy of an ERRb/g agonist DY131 (Yu and Forman, 2005) on ERRb-transduced prostate cancer cells. The transactivation capacity of DY131 on ERRb-activated ERE 3 -Luc and ERRE 3 -Luc reporters were assessed in HEK293 cells. Administration of DY131 at micromolar levels further stimulated ERRbactivated ERE-and ERRE-driven luciferase activities in HEK293 cells in a dose-dependent manner (Figure 10a ). We then examined and compared the growth inhibitory (Figure 10d ). The result was further confirmed in DU145 cells (express only ERRb) that ERRb knockdown could reduce the DY131-induced growth inhibition in both parental and infected cells. Taken together, our results showed that the DY131-induced growth inhibition in parental LNCaP and DU145 cells could be largely mediated via endogenous ERRb.
Discussion
In the present study, we manifested by RT-PCR using isoform-specific primer sets that only the short-form ERRb isoform, but not other splice variants, was expressed in human prostatic immortalized and cancer cell lines. By immunohistochemistry, we demonstrated that ERRb was expressed as a nuclear protein in both epithelial and stromal cells in fetal and pubertal prostates, whereas its nuclear expression becomes reduced in adult and aged prostates. By RT-PCR and immunohistochemical analyses, we reconfirmed our previous findings that ERRb exhibits a downregulation pattern in most prostate cancer cell lines, premalignant and malignant lesions in clinical prostatic neoplastic tissues. We further demonstrated by in vitro treatments with epigenetic modifiers that downregulation of ERRb in prostate cancer cells was mostly attributed to histone deacetylation, with minor extent by DNA methylation.
We next determined the functional role of ERRb in growth regulation of prostate cancer cells and demonstrated that ectopic expression of ERRb could inhibit significantly the cell proliferation and tumorigenicity of LNCaP and DU145 prostate cancer cells. We further elucidated by flow cytometry that the growth inhibition induced in ERRb infectants was mediated through a suppression of cell-cycle progression at S phase and inhibition of DNA synthesis but not apoptosis. We also showed that the LNCaP-ERRb cells acquired an NE-like differentiation phenotype, which was accompanied with an increased NSE expression and a ERRb-activated p21 transactivation was potently stimulated (3-9 folds) by co-transfection with PGC-1a dose dependently in 293 and HeLa cells (bars 1-6). Transfection with PGC-1a alone could only minimally activate the p21-Luc reporter (bars 7-11). Results were expressed as fold of activation compared to control (transfection with pcDNA) and obtained from triplicates repeated in three independent experiments. ChIP, chromatin immunoprecipitation; ERRb, estrogen-related receptorb; IP, immunoprecipitate; PGC-1a, peroxisome proliferatoractivated receptor-g coactivator-1a.
ERRb suppresses prostate cancer cell growth S Yu et al acid b-oxidation as the dominant bioenergetic pathway in prostate cancer cells (Liu, 2006) . Cumulative evidences indicate that another ERR subtype, ERRa, plays significant roles in energy metabolism and mitochondrial biogenesis in certain target cells and tissues via direct regulation of genes involved in fatty acid oxidation, ERRb suppresses prostate cancer cell growth S Yu et al glucose metabolism, oxidative phosphorylation and mitochondrial fusion Huss et al., 2004; Schreiber et al., 2004; Wende et al., 2005; Soriano et al., 2006; Villena et al., 2007) . Moreover, ectopic ERRa expression can promote lipid accumulation in primary cardiac myocytes (Huss et al., 2004) , whereas its loss of function reduces body fat in ERRa-knockout mouse (Luo et al., 2003) . In a recent expression profiling study of all 49 NRs in mouse tissues, ERRb is shown to be widely and rhythmically expressed in many organ systems, suggesting that ERRb together with other NRs are important in maintaining global basal metabolism under circadian control Yang et al., 2006) . Taken together, our present data provide indirect evidence that ERRb may be involved in energy metabolism and mitochondrial biogenesis, similar to its close relative ERRa. Our results suggest that targeting to ERRb via its effect on mitochondria and lipid metabolism could be a potential approach to inhibit prostate cancer growth. However, the signaling pathways mediated by ERRb in these metabolic processes and mitochondrial biogenesis are unclear.
By immunoblot analysis, we further showed that the ERRb-induced suppression of cell-cycle progression at S phase in LNCaP-ERRb and DU145-ERRb cells was accompanied with elevated p21 protein expression. As p21 is a key regulator of cell-cycle progression and plays critical role in the G 1 /S transition, it is believed that the S-phase blockade in ERRb-transduced prostate cancer cells may be partially mediated through increased levels of p21. The inhibition of DNA replication in ERRbtransduced cells could be caused by elevated p21 levels, as it is well characterized that p21 can directly inhibit DNA replication by its blocking of proliferating cell nuclear antigen (PCNA)-dependent DNA polymerase-d activity (Waga et al., 1994) . We showed by reporter and ChIP assays that ectopic ERRb could directly bind to and transactivate the p21 gene promoter in prostatic and non-prostatic cells, indicating that p21 was an ERRb target gene and the elevated p21 levels in ERRbtransduced prostate cancer cells were result of direct transactivation of p21 gene, besides other possible growth inhibitory signals. Recently, Castet et al. (2006) show that ERRb can activate the p21 gene promoter via Sp1 binding sites and at levels higher than ERRa and ERRg in HeLa cells. We recently demonstrated that another ERR isoform ERRg could also transactivate the p21 gene promoter in prostate cancer cells (Yu et al., 2007) . Taken together, ERRb and ERRg could co-target to p21 gene and regulate the cell-cycle control in prostate cancer cells. We also demonstrated that the ERRb-mediated p21 transactivation could be potently enhanced by PGC-1a, a characterized coactivator of ERRa/g (Huss et al., 2002; Ichida et al., 2002) and also a strong activator of mitochondrial function and regulator of cellular energy metabolism (Puigserver and Spiegelman, 2003) . Finally, we demonstrated by truncation analysis that ERRb-mediated p21 transactivation and growth inhibition would require intact DBD and LBD/AF2 domains in ERRb for its DNA and coactivator binding, as deletions of these domains could abolish its transactivation capacity and growth inhibitory effect in prostatic and non-prostatic cells.
Our cell synchronization experiments revealed a cellcycle-associated expression pattern of ERRb in ERRbtransduced prostate cancer cells and non-transduced 293 cells that either ectopic or native ERRb exhibited a higher expression in cells at interphase but it became reduced in G 2 /M phase, whereas it became lost during mitosis. These results together with the blockade of cellcycle progression at S phase by ERRb suggest that ERRb may arrest the proliferating cells at G 0 /G 1 phase. Intriguingly, AR also demonstrates a downregulation or degradation pattern during mitosis in androgen-sensitive prostate cancer cells (Litvinov et al., 2006) . Besides its well-characterized roles in regulation of prostatic cell growth and differentiation via regulation of its target genes, AR is also shown to play a novel role in DNA replication in prostate cancer cells via a mechanism of forming pre-replicative complexes with some transcriptional co-regulatory proteins at DNA replication foci and such complexes become degraded during mitosis by a proteasome-dependent pathway, thus restricting only one round of DNA replication per cell cycle (Sharma et al., 2003; Huang et al., 2005) . On the basis of the analogous degradation expression pattern shown by AR during cell-cycle progression, we speculate that ERRb may also perform similar function as a licensing factor for DNA replication in proliferating prostate cancer cells. However, further experiments are required to support this hypothesis.
Our present and also previous stable expression studies (Yu et al., 2007) revealed that both ERRb and ERRg demonstrate an antiproliferative or tumorsuppressing function in prostate cancer cells. It would be interesting to compare the effects of their ectopic expressions in prostate cancer cells to gain further insight in their roles in prostate cancer growth regulation. Both ERR isotypes could commonly induce growth inhibition in LNCaP and DU145 cells (suppression of in vitro cell proliferation, colony formation in soft agar and tumorigenicity in immunodeficient mice, cell-cycle arrest at G 1 /S transition and p21 induction), suggesting that both ERR isotypes may regulate prostate cancer cell growth via similar pathways or regulation of common target genes. These common effects could be attributed to their similarities in protein structures, particularly their DBD that share 100% homology (Chen et al., 1999; Lui et al., 2006; Zhou et al., 2006) . On the contrary, some phenotypic differences are also noted in ERRb-and ERRgtransduced prostate cancer cells. Induced NE-like transdifferentiation, altered mitochondrial structure and lipid accumulation were observed in ERRb-LNCaP cells but not in ERRg-LNCaP; whereas p27 expression was induced in ERRg-transduced prostate cancer cells but not in ERRb-transduced cells, suggesting that ERRb may have additional roles in mitochondrial physiology and lipid metabolism and two ERR isotypes may regulate different cell-cycle regulators in prostate cancer cells. However, the mechanisms involved remain to be elucidated.
Lastly, we evaluated the therapeutic efficacy of a selective ERRb/g agonist DY131 on in vitro prostate cancer cell growth. The proliferation studies showed that DY131 at micromolar levels could further potentiate the ERRb-mediated growth inhibition in ERRbtransduced prostate cancer cells compared to their parental cells. RNA interference results showed that the inhibitory effect of DY131 on parental LNCaP and DU145 cells was mediated via their endogenously expressed ERRb. Our cell-based studies suggest a potential therapeutic strategy that selective ERR ligands, which influence ERR-mediated signaling pathways, can exert an antiproliferating action by activating tumor-suppressing activities in prostate cancer cells and this could represent a novel approach, supplementing the conventional hormonal therapies, to inhibit prostate tumor growth and progression.
In summary, we here demonstrated that ERRb overexpression inhibited the cell growth of androgensensitive and -insensitive prostate cancer cells via a cellcycle blockade at S phase, revealing an antiproliferating role of ERRb in prostate cancer. We further showed that p21 was an ERRb-target gene, with its transactivation further potentiated by PGC-1a. Together with its downregulated expression pattern in prostate cancer cell lines and clinical tissues, our findings suggest that ERRb may perform a tumor-suppressing function in prostate cancer. Finally, we demonstrated that ERRb could be a potential therapeutic target for prostate cancer treatment, as ERRb-mediated growth inhibition in prostate cancer cells could be potentiated by selective ERRb/g agonist.
Materials and methods
Cell lines and cell culture Nine immortalized human prostate epithelial cell lines (RWPE-1, RWPE-2, PZ-HPV-7, HPr-1, HPr-1AR, PWR-1E, PNT1A, PNT2 and BPH-1) and seven prostate cancer cell lines (CA-HPV-10, LNCaP, C4-2B, DU145, PC-3, MDAPCa2b and CWR22Rv1) were used in this study. The cell lines were obtained from ATCC (American Type Culture Collection), ECACC (European Collection of Animal Cell Cultures) and other investigators and cultured in conditions as described previously (Cheung et al., 2005) .
Human prostatic tissues and immunohistochemistry
Immunohistochemistry of ERRb was performed on archival paraffin blocks of formalin-fixed fetal, pubertal, neoplastic human prostates using an enhanced immunoperoxidase procedure (Chan et al., 1999; Cheung et al., 2005) . All human tissues were obtained with informed consent and approval from the Clinical Research Ethics Committee, CUHK.
DNA de-methylation and histone deacetylase inhibitors treatment For epigenetic modification studies, cultured LNCaP, DU145 and PC-3 cells were treated with (i) a DNA methylation inhibitor 5-Aza-dC (5 mM) for 4 days with medium renewed daily and (ii) two histone deacetylase inhibitors TSA (0.5 mg ml
À1
) and NaBut (0.5 mM) for 48 h.
Molecular cloning and plasmid construction
Full-length human short-form ERRb cDNA (GenBank accession no. AY451389) was amplified by RT-PCR from total RNA of HEK293 cells, tagged with FLAG and cloned into pcDNA3.1 for transfections and pBabe-puro for retroviral infection, yielding pcDNA3.1-ERRb and pBabe-ERRb, respectively. pcDNA4-myc-PGC-1a was provided by Dr Finkel (Ichida et al., 2002) . FLAG-tagged ERRb-truncated mutants, ERRbDZF1, ERRbDLBD-AF2 and ERRbDAF2, were generated by fusion PCR method and cloned into pcDNA3.1 and pBabe (Figure 9a ). Human p21 gene promoter sequence (À2324 ± 11) was amplified by PCR from genomic DNA extracted from DU145 cells and cloned into pGL3 as pGL3-p21-Luc. All plasmid constructs were confirmed by DNA sequencing.
Retroviral transduction and generation of ERRb-stable clones pBabe-ERRb and pBabe-puro was transfected into mouse packaging PA317 cells using FuGENE 6 reagent. After 48-72 h, culture medium containing infectious virions was harvested for infection. LNCaP and DU145 cells were infected with the virus-containing media mixed with 8 mg ml À1 polybrene. After 48-h incubation, puromycin was added to eliminate the non-infected cells, and the stable clones were isolated after 8-day drug selection.
Cell synchronization
Stable ERRb clones and parental cells were cultured to 60% confluence and treated with a double-thymidine block to arrest cells at G 1 /S phase. Briefly, cells were blocked with 2 mM thymidine for 16 h, released for 8 h and retreated with thymidine. After 18-h treatment, cells were harvested or further treated with 100 ng ml À1 nocodazole for another 12 h to obtain cell populations at G 2 /M phase. Cell-cycle progression of synchronized cells were monitored by flow cytometry and harvested for immunoblot analysis.
RT-PCR analysis
Total RNA was extracted from 70 to 80% confluence cultured cells using TRIzol reagent. One microgram of DNase I-treated RNA samples was reverse transcribed to cDNAs by M-MLV reverse transcriptase using oligo(dT) 12-18 and 1 ml cDNA samples was used for PCR amplification, using primer pairs specific for three ERRb isoforms according to Zhou et al. (2006) .
Immunoblot analysis
Total cellular or nuclear proteins, extracted from 70% confluence cultured cells, were separated by sodium dodecyl sulfate-PAGE and transblotted onto polyvinylidene difluoride membranes (Cheung et al., 2005) . Transblotted membranes were probed with primary antibodies followed by a colorimetric method for immunosignal detection. Primary antibodies used are as follows: an affinity-purified rabbit ERRb antibody (Cheung et al., 2005) , a mouse monoclonal ERRb antibody (R&D Systems, Minneapolis, MN, USA), AR (Upstate, Lake Placid, NY, USA); cyclin A (Santa Cruz Technology, Santa Cruz, CA, USA); cyclin B1 and p53 (Cell Signaling, Danvers, MA, USA), cyclin D1 and D3, p21 and p27 (Lab Vision, Fremont, CA, USA), NSE (Dako, Denmark).
Cell counting and BrdU labeling (a) Cell counting: ERRb clones and parental cells, plated at 5 Â 10 3 per well in 24-well plates, were cultured for 10 days. Viable cells were counted daily by trypan blue-exclusion assay. (b) BrdU labeling: Cells grown to 70% confluence were trypsinized and seeded at same density onto 13-mm coverslips plated in 24-well plates. After 24-h culture, cells were incubated with 10 mM BrdU for 1 h and fixed in cold methanol-acetone solution (1:1) for 15 min. After pretreatment with 2 N HCl for 30 min at 37 1C, cells were stained with a mouse monoclonal anti-BrdU antibody followed by a FITC-labeled anti-mouse IgG. Labeled cells were counted under a fluorescent microscope followed by morphometric analysis (Neurolucida-2000; Neurolucida, Williston, VT, USA). Percentages of BrdU-positive cells were determined by counting at least 1 Â 10 3 cells in both ERRb clones and parental cells. Results were obtained from three independent experiments.
Apoptosis and cell-cycle analyses ERRb clones and parental cells were grown to 70% confluence for flow cytometry. After trypsinization, unfixed apoptotic cells were determined by an FITC-AV-PI double-labeling method (ApopNexin apoptosis detection kit; Chemicon, Temecula, CA, USA) and analysed by bivariate DNA flow cytometry (ALTRA Cell Sorting System; Beckman, Fullerton, CA, USA). Trypsinized cells (1 Â 10 6 ) fixed in 70% ethanol overnight at À20 1C were resuspended in a DNA-staining solution (10 mg ml À1 DNase-free RNase and 50 mg ml À1 PI in 0.85% NaCl) for FACS, followed by cell-cycle analysis (MoFit LT2, Topsham, ME, USA).
Cellular staining of mitochondria and lipid (a) Vital staining of mitochondria: Sub-confluent cells, seeded onto chamber slides were incubated with a dual-emission potential-sensitive fluorescent probe JC-1 (5 mM; Molecular Probes, Eugene, OR, USA) in culture medium for 15 min and washed in PBS. Stained vital cells were examined directly under a confocal scanning microscope (Bio-Rad MR1024, Hercules, CA, USA). (b) Oil-red-O staining: Cells seeded onto glass coverslips plated on 24-well plates were grown to 70% confluence and fixed in 4% paraformaldehyde. After washing in PBS, cells were incubated in an Oil-red-O solution for 15 min and differentiated in isopropanol.
Electron microscopy Cells grown to sub-confluence were fixed in 2.5% glutaraldehyde in phosphate buffer for 30 min, post-fixed in a reduced osmium solution (1% OsO 4 and 1.5% potassium ferrocyanide) for 30 min, washed in distilled water, dehydrated in graded ethanols and embedded in Epon 812 resin. Thin sections were cut, counterstained in uranyl acetate and lead citrate, and examined in a transmission electron microscope (Hitachi H-7100FA) at 75 kV.
Soft agar assay
Cells were suspended in culture media with 0.3% agar and plated at 5 Â 10 3 cells per well on six-well plates pre-coated with 0.5% base agar. After 28-day culture, cells were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet. Stained colonies with diameter over 100 mm were counted under a dissecting microscope.
In vivo tumorigenicity assay Stable ERRb clones and their parental cells (suspended in 100 ml 1:1 growth medium-Matrigel mixture) were subcutaneously injected into the flanks of male SCID mice (3 Â 10 6 LNCaP cells per mouse) or nude mice (5 Â 10 6 DU145 cells per mouse) and allowed to propagate for 4-8 weeks. All mice were housed in an air-filtered pathogen-free condition. Tumor growth was monitored weekly. Tumor volumes (mm 3 ) were measured using the formula (length Â width Â height)/2. Tumor growth (mean±s.d. from three independent animals) was plotted against time. All animal experiments were performed in accordance with the laboratory animal guidelines and with approval from the Animal Experimentations Ethics Committee, CUHK.
Dual-luciferase reporter assay HeLa, HEK293, LNCaP, DU145 and PC-3 cells were seeded in 24-well plates 24 h before transfection. Cells were co-transfected with 0.2 mg reporter plasmid (pGL3/pGL3-ERE/pGL3-ERRE/pGL3-p21-Luc), 0.2 mg expression plasmid (pcDNA3.1/pcDNA3.1-ERRb/ERRbDZF1/ERRbDLBD-AF2/ ERRbDAF2), 0.04 mg pRL-CMV, with or without pcDNA4-myc-PGC-1a, using FuGENE6 reagent. After 48-h posttransfection, cells were harvested for luciferase reporter assay using the dual-luciferase reporter assay system (Promega, Madison, WI, USA). The activated luciferase activity was normalized to that of the internal control Renilla luciferase activity by pRL-CMV as relative luciferase unit and fold of relative luciferase activation unit compared to control transfection with pcDNA3.1 was determined. All assays were performed in three separate experiments repeated in triplicate.
ChIP assay HEK293 cells were transfected with pcDNA3.1/pcDNA3.1-ERRb/pcDNA3.1-ERRbDZFI. Cells were cross-linked with 1% formaldehyde. After washing with cold PBS, cells were lysed in a cell-lysis buffer (10 mM, pH 8.0, 10 mM NaCl, 0.5% NP40, protease inhibitors) for 10 min on ice. Nuclei were collected by centrifugation and further lysed in a nuclear-lysis buffer (50 mM Tris-HCl, pH 8.1, 1% sodium dodecyl sulfate, 10 mM EDTA, protease inhibitors). Nuclear lysates were sonicated to shear DNA to 300-1000 bp fragments. After preclearing with protein-G-agarose, chromatin extracts were immunoprecipitated with ERRb antibodies overnight at 4 1C with rotation or no antibody as a negative control. Chromatin-protein-antibody complexes were precipitated with protein-G-agarose and washed extensively with buffers. After reverse-crosslink and removal of RNA and protein, DNA fragments were extracted with phenol-chloroformisopropanol. Precipitated DNA was analysed by PCR (30 cycles) with primer pairs specific for human p21 promoter (5 0 -TGAGCCTCCCTCCATCCCT-3 0 ; 5 0 -AAATAGCCACC AGCCTCTTCT-3 0 ).
RNA interference
Specific sequence target to ERRb (GCACAAACTCTTCCTG GAGAT) was cloned into pLKO.1-puro vector and delivered into the target cells by lentiviral system (Stewart et al., 2003) . pLKO.1-scramble containing scrambled sequence was used as control. For gene knockdown of ERRg, retroviral plasmid pRS-shRNA-ERRg (with sense insert sequence 5 0 -CACATTT GTTGGTGGCTGAACCG-3 0 ; Origene, Rockville, MD, USA) expressing shRNA targeting to ERRg was used. Supernatant with viral particles was collected 48 h after transfection. For transient knockdown of ERRb/g, cells were infected with viral supernatant in the presence of 8 mg ml
À1
polybrene for 24 h.
In vitro treatment with ERR agonist For MTT assay, cells were seeded at 2 Â 10 3 cells per well onto 96-well plates. After 24-h culture in growth media, cells were treated with an ERR agonist DY131 (Tocris, Ellisville, MO, USA) at doses ranging from 0.1 to 20 mM for 5 days with media renewed every 2 days. Viable cells were determined by incubating with MTT in culture media for 3 h, followed by A 490 measurement in a microplate reader. For reporter assay, cells were seeded in 24-well plates. After 24-h culture, cells were co-transfected with the reporters, expression plasmids and pRL-CMV at same amounts as mentioned above. After 12-h post-transfection, cells were treated with DY131 at various doses. After 36-h treatments, cells were harvested for luciferase reporter assay as mentioned above.
Statistical analysis
All results are expressed as mean ± s.d. Statistical analyses of data were performed using two-tail Student's t-test and differences were considered significant where Po0.01.
